Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q2 EPS of $1.29, $0.07 better than the analyst estimate of $1.22. Revenue for the quarter came in at $96.04 million versus the consensus estimate of $92.24 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.